Table of Contents Table of Contents
Previous Page  682 / 812 Next Page
Information
Show Menu
Previous Page 682 / 812 Next Page
Page Background

S678

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Introduction

Bupropion is a dual antidepressant, a nore-

pinephrine and dopamine reuptake inhibitor. Its main use is in

affective disorders as major depression. Antidepressants have been

commonly associated with sexual side effects in the libido, sex-

ual arousal, orgasm and erectile function. Bupropion has negative

influence in sexual function, even it could increase the libido. Due

to this, it could be a good option in patients with active sexual life

and affective disorder.

Clinical report

A58-year-old femalewith a long history of depres-

sion disorder for 5 years. History of lots of side effects with different

treatments, sexual dysfunction with serotonin-antidepressants.

Treated with bupropion SR 150mg/day and alprazolam, she suf-

fered a relapse. The bupropion was increased to 300mg/day. Three

days later she appeared in the consultation room, presented a sense

of pre-orgasmic of 72 hours of evolution, high increased libido,

tiredness, muscle tension and insomnia. This sense did not improve

after the sexual act. It had never happened previously. The side

effect improved when the bupropion was reduced to 150mg/day

and disappeared with its withdrawal.

Conclusions

The case made a relationship between the increased

of bupropion’s dose and the appearance of unusual sexual side

effects (increased of libido and pre-orgasmic sense). Not only

bupropion is one of the antidepressants that do not cause sexual

dysfunction, if not it was reported in some trials that could be a

treatment against this dysfunction due to its prosexual effects. The

mechanism is unknown but could be related with norepinephrine

or dopamine transmission.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2013

EV1029

Lithium treatment and thyroid

dysfunction – data from an inpatient

psychiatric department

M. Lázaro

1 ,

, A . M

ota

1 , A. M

oreira

2 , R. A

lves

1 , M.A

. Nobre

1

1

Centro Hospitalar Psiquiátrico de Lisboa, Clínica 5, Lisbon, Portugal

2

Área de Pedopsiquiatria, Centro Hospitalar Lisboa Central, H.D.

Estefânia, Lisboa, Portugal

Corresponding author.

Introduction

Lithium is among the most effective therapies

for bipolar disorder. Lithium treatment may cause hypothy-

roidism, goiter or to a lesser extent hyperthyroidism, since it

can affect several aspects of thyroid functioning. The prevalence

of lithium-associated hypothyroidism varies extensively between

studies, reaching up to 47%, and affecting more females than

males (5:1).

Objective

Determine the prevalence of thyroid dysfunction in an

acute inpatient psychiatric department dedicated to affective dis-

orders and its association with lithium therapy.

Aims

To review the relation between lithium treatment and thy-

roid dysfunction.

Methods

Observational, descriptive and retrospective study with

clinical and laboratorial data concerning all inpatient episodes of

2015 in our Psychiatric Department. A non-systematic literature

search was performed in PubMed.

Results

The present study documented a high prevalence of thy-

roid dysfunction, particularly in women. Most cases were due

to either hypothyroidism or subclinical hypothyroidism. Patients

treated with lithium were more often under thyroid hormone

replacement therapy (levothyroxine).

Conclusions

The evidence that lithium treatment is associated

with hypothyroidism is well established and this condition is easily

treatable with levothyroxine. This study highlights the importance

of baseline screening of thyroid function and regular long-term

monitoring in patients treated with lithium.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2014

EV1030

Do patients with psychotic disorders

who smoke need higher dose of

antipsychotic?

G. Ledesma-Iparraguirre

1 ,

, S . L

opez-Romeo

1 , A. A

hicart-Rosell

1 ,

N. Pastrana-Rocher

1

, G. Saenz-Navarrete

1

, N. Del Cacho

1

,

V. Barneda

1

, J. Usall

1 , 2 , 3

, E. Rubio-Abadal

1 , 2 , 3

1

Research and Development Unit, Parc Sanitari Sant Joan de Déu,

Sant Boi de Llobregat, Barcelona, Spain

2

Grup de Treball de Dona i Salut Mental, GTRDSM, Barcelona, Spain

3

Centro de investigación biomédica en red de salud mental,

CIBERSAM, Barcelona, Spain

Corresponding author.

Introduction

Prevalence of tobacco use in patients with psychotic

disorders (PD) is 40–70%. It has been described use of tobacco

induces Cytochrome P450 activity, increasing some antipsychotic

drugs metabolism, thus reduces their plasma levels.

Aim

We carried out the present study to analyze the associa-

tion between tobacco use and doses of antipsychotics in patients

with PD and to determine whether patients suffering from PD who

smoke may require antipsychotic dose adjustments.

Methods

We designed a cross-sectional study of patients

between 18 and 55 years, with a PD, treatedwith the same antipsy-

chotic and dose for the last 6 months:

– consumption of cigarettes per day was determined;

– the doses of the used antipsychotic drugs were converted into

chlorpromazine equivalents;

– statistical analysis was performed with STATA.

Results

The sample consisted of 30 women (29.7%) and 71 men

(70.3%). Mean age was 43.7 years old (SD: 8.0). Sixty-three patients

were smokers (63.6%), being the other 36 non-smokers (36.4%).

Mean dose of chlorpromazine in smokers was 1088.04mg/day

(SD: 697.17mg/day) whether in non-smokers was 699.16mg/day

(SD: 556.07mg/day). Mean differences of antipsychotic dose were

statistically significant between the two groups of smokers and

non-smokers (

P

= 0.005). We also found significant association

between consumption of cigarettes and antipsychotics doses

(

P

= 0.0001), so that, per each cigarette/day, dose of Chlorpromazine

increased 19.81mg/day.

Conclusion

Patients suffering from PD smoke required higher

doses of antipsychotics. These results suggest that patients who

smoke might need higher doses of antipsychotic and that, if con-

sumption of tobacco varies, antipsychotics doses might need to be

adjusted.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2015

EV1031

Metabolic syndrome and its

association with psychotropic

medications in psychiatric patients

from CAISM–IGSS (Center for

Comprehensive Care Mental

Health/Guatemalan Institute of Social

Security)

J. Lopez

Guatemala

Introduction

The use of antipsychotics represents an integral

part of the psychiatric practice, unfortunately the use seems to